Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma

International Urology and Nephrology

Volumn 44, Issue 1, 2012, Pages 111-117

  Lin, Ying Li ^a,b   Liu, Xiao Qiang ^a,b   Li, Wen Ping ^c   Sun, Guang ^b   Zhang, Chun Ting ^a,b  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Institute of Urology   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Bladder cancer; H cadherin; Methylation; Transitional cell carcinoma

Indexed keywords

CADHERIN; GENOMIC DNA; H CADHERIN; UNCLASSIFIED DRUG; DNA; H-CADHERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER EPITHELIUM; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; TUMOR VOLUME; BLADDER TUMOR; DNA METHYLATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, TRANSITIONAL CELL; DNA; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84861158226     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-9961-6     Document Type: Article

References (33)

1. Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430-442
2. Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289-293
3. Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60: 244-272
4. Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283-285
5. Black PC, Dinney CP (2007) Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26:623-634
6. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Saga-lowsky AI, Schoenberg MP, Lerner SP (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414-2422
7. Herr HW, Dotan Z, Donat SM, Bajorin DF (2007) Defining optimal therapy for muscle invasive bladder cancer. J Urol 177:437-443
8. Morgan TM, Clark PE (2010) Bladder cancer. Curr Opin Oncol 22:242-249
9. Andreeva AV, Kutuzov MA (2010) Cadherin 13 in cancer. Genes Chromosomes Cancer 49:775-790
10. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ (2008) Promoter hypermethylation of CDH13 is a com-mon, early event in human esophageal adenocarcinogene-sis and correlates with clinical risk factors. Int J Cancer 123:2331-2336
11. Kim DS, Kim MJ, Lee JY, Kim YZ, Kim EJ, Park JY (2007) Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer 110:2785-2792
12. Dehan P, Kustermans G, Guenin S, Horion J, Boniver J, Delvenne P (2009) DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn 9: 651-657
13. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229
14. Kim YK, Kim WJ (2009) Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 16:17-22
15. Enokida H, Nakagawa M (2008) Epigenetics in bladder cancer. Int J Clin Oncol 13:298-307
16. Maruyama R, Toyooka S, Toyooka KO, Harada K, Vir-mani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61:8659-8663
17. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, Gao B, Wang W, Gu L, Meng J, Wang J, Feng X, Li Y, Yao X, Zhu J (2007) A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13:7296-7304
18. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C (2002) Guidelines on bladder cancer. Eur Urol 41:105-112
19. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E (2007) Tumor-specific downregula-tion and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20:1269-1277
20. Kim JS, Han J, Shim YM, Park J, Kim DH (2005) Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 104:1825-1833
21. Sakai M, Hibi K, Koshikawa K, Inoue S, Takeda S, Kaneko T, Nakao A (2004) Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Sci 95:588-591
22. Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A (2004) Methylation pattern of CDH13 gene in digestive tract cancers. Br J Cancer 91:1139-1142
23. Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M (2004) CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109:163-166
24. Kim WJ, Kim YJ (2009) Epigenetic biomarkers in uro-thelial bladder cancer. Expert Rev Mol Diagn 9:259-269
25. Jung S, Jeong D, Kim J, Yi L, Koo K, Lee J, Lee SD, Park JW, Chang B, Kim CH, Kim CJ, Lee MS (2010) The role of hLHX6-HMR as a methylation biomarker for early diagnosis ofcervical cancer. Oncol Rep 23:1675-1682
26. Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, Liu JC, Crijns AP, Brown R, Nephew KP, van der Zee AG, Cohn DE, Yan PS, Huang TH, Lin HJ (2009) Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22:853-861
27. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239-249
28. Lopez-Beltran A (2008) Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 218: 95-109
29. Yan Q, Zhang ZF, Chen XP, Gutmann DH, Xiong M, Xiao ZY, Huang ZY (2008) Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. Int J Oncol 32:1057-1063
30. Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG (2008) Effect of DNA methylation on identification of aggressive prostate cancer. Urology 72: 1234-1239
31. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118-1128
32. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218:12-20
33. Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, Lackmichi A, Ricci S, Lacave R, Gattegno B, Richard F, Hamdy FC, Cussenot O (2008) A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 101:1448-1453